Hematology

The FDA has requested additional preclinical data from Beam Therapeutics on BEAM-201.

Of 55 evaluable patients in ZUMA-3, 71% achieved complete remission (CR) or CR with incomplete hematological recovery (CRi).

The director of myeloma immunotherapy at University of Pennsylvania discussed cilta-cel's efficacy in lenalidomide-refractory multiple myeloma.

Review top news and interview highlights from the week ending September 2, 2022.

The in vivo genome-editing therapy is the first gene therapy to be evaluated in a clinical trial for preventing HAE attacks.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

A pre-treatment TME with high levels of cytokines and chemokines was associated with complete response to axi-cel treatment.

The primary investigator and chief of hematology at Children’s Hospital of Philadelphia discussed the collaboration and research that went into developing beti-cel.

The company has initiated the world’s first confirmatory phase 2 trial of a CAR T-cell therapy in solid tumors.

The tumor-infiltrating lymphocyte therapy has shown efficacy in the phase 2 C-144-01 trial.

Review top news and interview highlights from the week ending August 26, 2022.

The senior vice president and head of medical affairs at Orca Bio discussed how Orca-T has been developed to lower the risk of graft-versus-host disease.

Century Therapeutics will initiate the phase 1 ELiPSE-1 study imminently.

The senior vice president of immunology at Cellectis discussed the company’s investigational dual-targeted CAR-T therapy for B-cell malignancies.

BioMarin plans to resubmit the biologics license application for val-rox to the FDA by the end of September 2022.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The primary investigator and chief of hematology at Children’s Hospital of Philadelphia discussed requirements for administering beti-cel.

At a median follow-up of 24 months, the best ORR achieved was 77.6% among 58 evaluable patients with large B-cell lymphoma treated with relma-cel.

The senior vice president and head of medical affairs at Orca Bio discussed the initiation of the Precision-T phase 3 trial.

Review top news and interview highlights from the week ending August 19, 2022.

Higher doses were associated with improved overall survival, event-free survival, and relapse-free survival.

The primary investigator and chief of hematology at Children’s Hospital of Philadelphia discussed beti-cel's approval.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

ZYNTEGLO is now the world's most expensive gene therapy at a $2.8 million price tag.

Tessa Therapeutics presented positive data from the phase 2 CHARIOT study of TT11 in December 2021.